What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To evaluate the safety and efficacy of venetoclax combined with obinutuzumab in untreated Japanese patients with CLL or SLL.

November 10, 2025International Journal of HematologyOpen Access

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study

View Full Paper

Ask AI

Bookmark

Authors

KIKoji Izutsu MWMitsumasa Watanabe TTTomomi Toubai

Discussion

Member takes

Implication

Phase 2 trial demonstrated high efficacy and manageable safety of venetoclax plus obinutuzumab in Japanese CLL patients, suggesting potential as a standard treatment.

Key Points

To evaluate the safety and efficacy of venetoclax combined with obinutuzumab in untreated Japanese patients with CLL or SLL.
Phase 2 trial
12-cycle regimen of venetoclax plus obinutuzumab
Evaluated complete remission and adverse events in Japanese patients
Independent Review Committee assessed results according to CLL criteria.
Complete remission/CRi rate of 90.0% observed
At least one treatment-emergent adverse event reported in all patients
Most common adverse events included infusion-related reactions (60%) and decreased neutrophil count (50%).

Cite This Study

Izutsu et al. (2025) studied this question.

synapsesocial.com/papers/69253a1ec0ce034ddc357155 https://doi.org/10.1007/s12185-025-04095-w

View Full Paper

Ask AI

Bookmark

Implication

Phase 2 trial demonstrated high efficacy and manageable safety of venetoclax plus obinutuzumab in Japanese CLL patients, suggesting potential as a standard treatment.

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider